AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21029199 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity running
Number of subjects: 20
Study 21029199 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle temperature
Number of subjects: 20
Study 21029199 — intervention group
Group type: EXPERIMENTAL
Intervention: Net fluid loss
Number of subjects: 20
Study 21029199 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlations
Number of subjects: 20
Study 21124684 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic carpal tunnel release (CTR)
Number of subjects: 61
Study 21124684 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release (CTR)
Number of subjects: 61
Study 15857102 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.50 mg/ml rhBMP‐2/ACS
Number of subjects: 80
Study 15857102 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/ml rhBMP‐2/ACS
Number of subjects: 80
Study 15857102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (ACS alone)
Number of subjects: 80
Study 15857102 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 80
Study 12183244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (1 g once a day)
Number of subjects: 592
Study 12183244 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (1 g daily)
Number of subjects: 592
Study 12183244 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem and Ceftriaxone
Number of subjects: 592
Study 10968433 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat (40 mg daily for 24 weeks)
Number of subjects: 573
Study 10968433 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril (20 mg daily for 24 weeks)
Number of subjects: 573
Study 10968433 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 573
Study 8980437 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with transient carotid clamping
Number of subjects: 24
Study 1453199 — intervention group
Group type: EXPERIMENTAL
Intervention: ALTER regimen
Number of subjects: 533
Study 1453199 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance Tam
Number of subjects: 533
Study 1453199 — intervention group
Group type: COMPARATOR
Intervention: CMFPT
Number of subjects: 533
Study 1453199 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing Tam
Number of subjects: 533
Study 1453199 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of amenorrhea
Number of subjects: 533
Study 1453199 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreasing nodal involvement and ER+ status
Number of subjects: 533
Study 1453199 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone receptor-positive (PgR+) status and decreasing tumor size
Number of subjects: 533
Study 1453199 — intervention group
Group type: COMPARATOR
Intervention: Toxicity
Number of subjects: 533
Study 4095819 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice (low-sucrose, low-fat, high-fiber, energy-restricted) and exercise (individual or group) for 6 months
Number of subjects: 25
Study 4095819 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide, 1.25 mg daily added at breakfast for 10 subjects after 6 months of dietary and exercise treatment
Number of subjects: 25
Study 4095819 — intervention group
Group type: COMPARATOR
Intervention: Control group (18 GI subjects) with no treatment for 5-10 months
Number of subjects: 25
Study 30883942 — intervention group
Group type: EXPERIMENTAL
Intervention: rhBMP‐2‐soaked absorbable collagen sponge (test group)
Number of subjects: 64
Study 30883942 — intervention group
Group type: COMPARATOR
Intervention: β‐tricalcium phosphate and hydroxyapatite particles immersed in rhBMP‐2 (control group)
Number of subjects: 64
Study 27634838 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week behavioral nutrition intervention
Number of subjects: 50
Study 27634838 — intervention group
Group type: COMPARATOR
Intervention: Physical activity intervention
Number of subjects: 50
Study 26990598 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed schedule financial incentives
Number of subjects: 0
Study 26990598 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating schedule financial incentives
Number of subjects: 0
Study 26990598 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24784894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once-a-day
Number of subjects: 770
Study 24784894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg on demand
Number of subjects: 770
Study 24784894 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil 50 mg on demand
Number of subjects: 770
Study 22307061 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (CCRT) with adjuvant chemotherapy (Paclitaxel 135 mg/m² + Cisplatin 75 mg/m²)
Number of subjects: 880
Study 22307061 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiation (CCRT) alone
Number of subjects: 880
Study 19957087 — intervention group
Group type: EXPERIMENTAL
Intervention: PETN 80 mg t.i.d.
Number of subjects: 80
Study 19957087 — intervention group
Group type: COMPARATOR
Intervention: C
Number of subjects: 80
Study 17335950 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery training group
Number of subjects: 20
Study 17335950 — intervention group
Group type: COMPARATOR
Intervention: Control group (passively observing the task)
Number of subjects: 20
Study 15766834 — intervention group
Group type: EXPERIMENTAL
Intervention: Bare-metal stent (BMS)
Number of subjects: 2512
Study 15766834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 2512
Study 15766834 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 2512
Study 12021739 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity treadmill exercise at 75% O(2max) with placebo
Number of subjects: 6
Study 12021739 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise at 40% O(2max) with placebo
Number of subjects: 6
Study 12021739 — intervention group
Group type: COMPARATOR
Intervention: Naloxone treatment (10 mg)
Number of subjects: 6
Study 12021739 — intervention group
Group type: COMPARATOR
Intervention: No exercise control (placebo or naloxone)
Number of subjects: 6
Study 10448452 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive group psychoeducation
Number of subjects: 57
Study 10448452 — intervention group
Group type: COMPARATOR
Intervention: Control therapy
Number of subjects: 57
Study 8641319 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost (0.7 ng x kg x min(‐1))
Number of subjects: 14
Study 2086017 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 60
Study 2086017 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 20mg/d
Number of subjects: 60
Study 2086017 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem plus Aspirin
Number of subjects: 60
Study 2086017 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 60
Study 31065992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone ARIR 30 mg under fasted conditions
Number of subjects: 58
Study 31065992 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone ARIR 30 mg under fed conditions
Number of subjects: 58
Study 31065992 — intervention group
Group type: COMPARATOR
Intervention: IR oxycodone 30 mg under fasted conditions
Number of subjects: 58
Study 28470952 — intervention group
Group type: EXPERIMENTAL
Intervention: tolvaptan
Number of subjects: 1445
Study 25229335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 3636
Study 25229335 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 3636
Study 23084077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein-based oral supplement
Number of subjects: 14
Study 23084077 — intervention group
Group type: COMPARATOR
Intervention: No supplement (non-treated group)
Number of subjects: 14
Study 21617091 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted nurse/nephrologist-supported care
Number of subjects: 474
Study 21617091 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 474
Study 19625036 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia version of the American Urological Association symptom score
Number of subjects: 232
Study 19625036 — intervention group
Group type: COMPARATOR
Intervention: Traditional written version of the American Urological Association symptom score
Number of subjects: 232
Study 19625036 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia version for patients with low literacy
Number of subjects: 232
Study 19625036 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia version for patients with high literacy
Number of subjects: 232
Study 16908788 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline tartrate 1.0 mg twice daily
Number of subjects: 638
Study 16908788 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline tartrate 1.0 mg once daily
Number of subjects: 638
Study 16908788 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride 150 mg twice daily
Number of subjects: 638
Study 16908788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 638
Study 15243882 — intervention group
Group type: EXPERIMENTAL
Intervention: RFSNN technique for detecting H. pylori infection
Number of subjects: 104
Study 15243882 — intervention group
Group type: EXPERIMENTAL
Intervention: RFSNN technique for predicting gastric histological features
Number of subjects: 104
Study 11558289 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA with primary closure
Number of subjects: 510
Study 11558289 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA with patching (PTFE or vein patch closure)
Number of subjects: 510
Study 11558289 — intervention group
Group type: EXPERIMENTAL
Intervention: Patching using PTFE or vein patch closure
Number of subjects: 510
Study 11558289 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary closure
Number of subjects: 510
Study 11558289 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemashield patch
Number of subjects: 510
Study 9161395 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feeding (EF group, n = 29)
Number of subjects: 58
Study 9161395 — intervention group
Group type: COMPARATOR
Intervention: Traditional feeding (TF group, n = 29)
Number of subjects: 58
Study 8194142 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients
Number of subjects: 498
Study 8194142 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic controls
Number of subjects: 498
Study 8194142 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with hyperlipidaemia
Number of subjects: 498
Study 8194142 — intervention group
Group type: EXPERIMENTAL
Intervention: NIDDM patients with normolipidaemia
Number of subjects: 498
Study 3538964 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Maintenance Organization (HMO)
Number of subjects: 1522
Study 3538964 — intervention group
Group type: COMPARATOR
Intervention: Fee-for-Service System
Number of subjects: 1522
Study 29061382 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily meal distribution approach
Number of subjects: 206
Study 29061382 — intervention group
Group type: COMPARATOR
Intervention: Food voucher intervention
Number of subjects: 206
Study 27214055 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI)
Number of subjects: 82
Study 27214055 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Control (audiobook segments)
Number of subjects: 82
Study 24665971 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg F/g with 1% TMP
Number of subjects: 56
Study 24665971 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 μg F/g with 0.25% CaGP
Number of subjects: 56
Study 24665971 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 μg F/g
Number of subjects: 56
Study 23015748 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant treatment
Number of subjects: 376
Study 23015748 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous episodes categorized as less than 5, 5‐10, and more than 10
Number of subjects: 376
Study 20823381 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieved on‐treatment systolic BP levels in the first 24 hours
Number of subjects: 404
Study 20823381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive BP reduction to systolic levels between 130 and 140 mm Hg
Number of subjects: 404
Study 20823381 — intervention group
Group type: COMPARATOR
Intervention: Baseline systolic BP levels
Number of subjects: 404
Study 18491071 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (daily docosahexaenoic/eicosapentaenoic acid capsules, no other seafood; single-blinded)
Number of subjects: 324
Study 18491071 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean fish (150 g cod, three times/week)
Number of subjects: 324
Study 18491071 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatty fish (150 g salmon, three times/week)
Number of subjects: 324
Study 18491071 — intervention group
Group type: COMPARATOR
Intervention: Control (no seafood; single-blinded)
Number of subjects: 324
Study 16895641 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Cleavage Assessment (ECA)
Number of subjects: 196
Study 16895641 — intervention group
Group type: COMPARATOR
Intervention: Early Cleavage Not Assessed (ECNA)
Number of subjects: 196
Study 16895641 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ECA and ECNA)
Number of subjects: 196
Study 12970007 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized levalbuterol, 1.25 mg
Number of subjects: 30
Study 12970007 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic albuterol, 2.5 mg
Number of subjects: 30
Study 12970007 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined racemic albuterol, 2.5 mg, and ipratropium, 0.5 mg
Number of subjects: 30
Study 12970007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10381159 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diet (increased vegetable protein and soluble fiber)
Number of subjects: 31
Study 8678103 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime (1 g every 12 hours)
Number of subjects: 298
Study 8678103 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime (1 g every 8 hours)
Number of subjects: 298
Study 1906097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (8 mg/kg daily)
Number of subjects: 126
Study 1906097 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (40 mg/kg daily)
Number of subjects: 126
Study 1906097 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime and Amoxicillin
Number of subjects: 126
Study 6134671 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 6134671 — intervention group
Group type: COMPARATOR
Intervention: Pindolol
Number of subjects: 0
Study 6134671 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 0
Study 29878103 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to remain active (AA)
Number of subjects: 538
Study 29878103 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate physiotherapy (IP)
Number of subjects: 538
Study 29878103 — intervention group
Group type: COMPARATOR
Intervention: Advice to rest (AR)
Number of subjects: 538
Study 29878103 — intervention group
Group type: COMPARATOR
Intervention: Usual care physiotherapy (UCP)
Number of subjects: 538
Study 29139007 — intervention group
Group type: COMPARATOR
Intervention: RT-HIIT
Number of subjects: 240
Study 29139007 — intervention group
Group type: COMPARATOR
Intervention: AT-HIIT
Number of subjects: 240
Study 27178009 — intervention group
Group type: EXPERIMENTAL
Intervention: Low learning stimulation in the home at age 3
Number of subjects: 587
Study 27178009 — intervention group
Group type: EXPERIMENTAL
Intervention: Language delays in first grade
Number of subjects: 587
Study 27178009 — intervention group
Group type: EXPERIMENTAL
Intervention: Home learning environment at age 3
Number of subjects: 587
Study 24458078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol (1.02 g, 2 × 510‐mg injections)
Number of subjects: 162
Study 24458078 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (1.0 g, administered as slow injection or infusion)
Number of subjects: 162
Study 24458078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxytol
Number of subjects: 162
Study 24458078 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose
Number of subjects: 162
Study 22672407 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised care intervention involving a comprehensive assessment and regular telephone reviews over a 6-month period.
Number of subjects: 81
Study 22672407 — intervention group
Group type: COMPARATOR
Intervention: Usual general practitioner (GP) care
Number of subjects: 81
Study 22672407 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised care intervention
Number of subjects: 81
Study 20173678 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone position (group 1)
Number of subjects: 45
Study 20173678 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-chest position (group 2)
Number of subjects: 45
Study 20173678 — intervention group
Group type: COMPARATOR
Intervention: Both positions (prone and knee-chest)
Number of subjects: 45
Study 17824865 — intervention group
Group type: EXPERIMENTAL
Intervention: Short waiting time group (WT < or = 3 months)
Number of subjects: 310
Study 17824865 — intervention group
Group type: COMPARATOR
Intervention: Non-fixed waiting time group
Number of subjects: 310
Study 16897907 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation with metronomic beats imbedded in music
Number of subjects: 28
Study 16897907 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic auditory stimulation with metronomic beats without music
Number of subjects: 28
Study 16897907 — intervention group
Group type: COMPARATOR
Intervention: No auditory stimulus
Number of subjects: 28
Study 12072848 — intervention group
Group type: EXPERIMENTAL
Intervention: All 3 palpation procedures
Number of subjects: 29
Study 10325782 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline infusion
Number of subjects: 25
Study 10325782 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (Control)
Number of subjects: 25
Study 8961312 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Control Question Test with unambiguous questions
Number of subjects: 0
Study 2019314 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 or 3 mg/kg diazoxide given 2.5 min before laryngoscopy
Number of subjects: 30
Study 2019314 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study 6765414 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard amikacin dosing (15 mg/kg per day in four divided doses) with ticarcillin or piperacillin
Number of subjects: 0
Study 6765414 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetically adjusted amikacin dosing (mean dosage of 29.4 mg/kg per day) with ticarcillin or moxalactam
Number of subjects: 0
Study 6765414 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous amikacin-plus-ticarcillin trial with 15 mg/kg per day)
Number of subjects: 0
Study 29759944 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (cathode-F3/anode-F4 montage) at 2 mA for 20 min
Number of subjects: 28
Study 29759944 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 28
Study 28094468 — intervention group
Group type: EXPERIMENTAL
Intervention: inside‐out transobturator tension‐free vaginal tape (TO‐TVT)
Number of subjects: 341
Study 28094468 — intervention group
Group type: COMPARATOR
Intervention: outside‐in transobturator tape (TOT‐ARIS)
Number of subjects: 341
Study 25985046 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase cognitive therapy (CT) for 8 months
Number of subjects: 241
Study 25985046 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blinded fluoxetine for 8 months
Number of subjects: 241
Study 25985046 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo for 8 months
Number of subjects: 241
Study 25985046 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase treatments (CT, fluoxetine, placebo)
Number of subjects: 241
Study 24001030 — intervention group
Group type: EXPERIMENTAL
Intervention: ECA (Embodied Conversational Agent)
Number of subjects: 263
Study 24001030 — intervention group
Group type: COMPARATOR
Intervention: Control (pedometer only)
Number of subjects: 263
Study 24001030 — intervention group
Group type: EXPERIMENTAL
Intervention: ECA (Embodied Conversational Agent) for participants with adequate health literacy
Number of subjects: 263
Study 24001030 — intervention group
Group type: COMPARATOR
Intervention: Control (pedometer only) for participants with adequate health literacy
Number of subjects: 263
Study 21156438 — intervention group
Group type: EXPERIMENTAL
Intervention: True cooling
Number of subjects: 6
Study 21156438 — intervention group
Group type: COMPARATOR
Intervention: Sham cooling
Number of subjects: 6
Study 21156438 — intervention group
Group type: COMPARATOR
Intervention: No cooling
Number of subjects: 6
Study 19061808 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-implants for en-masse retraction (G1)
Number of subjects: 30
Study 19061808 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods of anchorage preservation (G2)
Number of subjects: 30
Study 17718288 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon cassia powder 1.5 g/d
Number of subjects: 60
Study 17718288 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 12723628 — intervention group
Group type: EXPERIMENTAL
Intervention: P54FP
Number of subjects: 61
Study 12723628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 11296163 — intervention group
Group type: COMPARATOR
Intervention: pMDI alone
Number of subjects: 12
Study 11296163 — intervention group
Group type: EXPERIMENTAL
Intervention: pMDI with small-volume plastic spacer
Number of subjects: 12
Study 11296163 — intervention group
Group type: EXPERIMENTAL
Intervention: pMDI with cardboard tube
Number of subjects: 12
Study 9283507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy added to group drug counseling
Number of subjects: 480
Study 9283507 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive psychodynamic therapy added to group drug counseling
Number of subjects: 480